Clinical Study on the Efficacy and Safety of SHR-4597 Inhalant in Adult Patients With Asthma

NCT ID: NCT06940700

Last Updated: 2025-04-23

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-04-30
• Study Completion Date: 2025-12-31

Brief Summary

To evaluate the efficacy and safety of SHR-4597 inhalants in adults with asthma: a multicenter, randomized, open-label, positive-controlled Phase II clinical study

Conditions

Asthma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Treatment group A

SHR4597

Group Type: EXPERIMENTAL

SHR4597

Intervention Type: DRUG

SHR4597

Treatment group B

SHR4597

Group Type: EXPERIMENTAL

SHR4597

Intervention Type: DRUG

SHR4597

Treatment group C

Budesonide inhalant

Group Type: ACTIVE_COMPARATOR

Budesonide inhalant

Intervention Type: DRUG

Budesonide inhalant

Interventions

SHR4597

SHR4597

Intervention Type: DRUG

Budesonide inhalant

Budesonide inhalant

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Age ≥18 years old and ≤75 years old, gender is not limited;

2. Body mass index (BMI) ≥18 and ≤30 kg/m2 during screening period;

3. Medical history and objective evidence consistent with current guidelines supporting an asthma diagnosis within the 12 months prior to randomization;

4. Did not receive inhaled corticosteroids (ICS) and/or combined with other asthma control medications within 2 weeks prior to randomization;

5. FEV1 during the screening period and before bronchodilator inhalation at baseline accounted for ≥40% and < 80% of the estimated value;

6. Screening and baseline visit, Asthma Control Questionnaire-6 (ACQ-6) score ≥1.5;

7. FeNO values at screening period and baseline ≥25 ppb;

8. Patients with asthma who were treated for the first time or who had previously taken irregular medication were selected; Among them, the definition of irregular past use was: patients did not regularly use asthma control drugs within the first 3 months of enrollment, and the average weekly use compliance was < 50%.

9. A fertile female subject or a male subject whose partner is a fertile female must agree not to have a family plan and to voluntarily use highly effective contraception (including the partner) from the time of signing the informed consent until 1 month after the last study drug administration, and refrain from sperm/egg donation;

10. Voluntarily sign informed consent to participate in this study.

11. The subjects were unable to complete the questionnaires due to their limited educational level, or neither the subjects themselves nor their families could fill in the subject log card.

12. The researchers determined that there were other circumstances that were not suitable for participation in this study.

Exclusion Criteria

1. Combined diseases or conditions

• Clinically significant pulmonary diseases, including but not limited to active pulmonary tuberculosis, bronchiectasis, atelectasis, idiopathic pulmonary fibrosis, bronchopulmonary aspergillosis, and chronic obstructive pulmonary disease (COPD);

• Malignant tumors diagnosed within 5 years prior to randomization (except those with a low risk of metastasis and death, such as well-treated basal cell carcinoma of the skin or carcinoma in situ of the cervix);

• Combined with poorly controlled hypertension (systolic blood pressure ≥180mmHg, and/or diastolic blood pressure ≥110mmHg during the screening period) or uncontrolled severe cardiovascular and cerebrovascular diseases; ④ Known immunodeficiency;

• A history of infection requiring clinical intervention within 4 weeks prior to randomization, including but not limited to respiratory infection;

⑥ Known presence of parasitic infection within 6 months prior to randomization;

⑦ Blood donation or significant blood loss (≥400ml), or transfusion of blood products or immunoglobulin within 4 weeks prior to randomization;

⑧ A history of life-threatening acute asthma attacks (including admission to the intensive care unit and/or the need for invasive ventilator support [intubation/tracheotomy]);

⑨ History of acute asthma attack in the 4 weeks prior to randomization.

2. Combination of medication or treatment

• Receiving non-selective beta-blockers (e.g., propranolol) within 1 week prior to screening;

• Live attenuated vaccine or recombinant vaccine with viral vector were received within 4 weeks before randomization;

• Receiving allergen immunotherapy 8 weeks before randomization;

• Within 12 weeks before randomization or within 5 half-lives of the drug (refer to the drug instructions, whichever is older; For those with unknown half-lives, the first 12 weeks of randomization will be the use of systemic immunosuppressants (except for systemic glucocorticoids for asthma treatment, and systemic glucocorticoids for other conditions <3 days) or immunomodulators, or biologics or Th2 cytokine inhibitors, Including but not limited to methotrexate, cyclosporine, interferon-alpha, anti-IL-5 monoclonal antibody,anti-TSLP monoclonal antibody, anti-IGE monoclonal antibody, mesulast, etc.

• Receiving a single dose of long-acting β2 agonist within 4 weeks prior to screening; ⑥4 weeks before randomization, inhaled corticosteroids (>500 micrograms of beclomethasone dipropionate per day [BDP] or equivalent dose);

⑦4 weeks before randomization, systemic glucocorticoid therapy;

• Received bronchial thermoplasty or bronchial cryoablation within 1 year before randomization; ⑨There is a surgical plan during the study, or other treatment that the investigator believes may affect the evaluation of the subject;

3. Laboratory examination

①Significant abnormalities during screening or baseline laboratory tests:

1. White blood cell (WBC) < 3.0×109/L;

2. Blood eosinophils >1500cells/μL (1.5×109/L)

3. Hemoglobin (Hb) ≤90 g/L;

4. Alanine aminotransferase (ALT) > 3×ULN (upper limit of normal);

5. Aspartate aminotransferase (AST) > 3×ULN;

6. Total bilirubin (TBIL) > 1.5×ULN;

7. Prothrombin time (PT) > ULN+3s;

8. Creatinine (Cr) > 1.5×ULN;

9. Co-active hepatitis B (peripheral blood hepatitis B virus deoxyribonucleic acid (HBV DNA) ≥1×103 IU[or copy] / mL), or hepatitis C antibody positive, or human immunodeficiency virus (HIV) positive, or treponema pallidum antibody positive.

• Prolonged ECG QTc interval (>450ms) or other clinically significant abnormal results that may pose significant safety risks to subjects during the screening period;

4. General situation

• Smoking or smoking cessation less than 6 months during the screening period, or previous smoking ≥10 pack years (pack years = number of years of smoking × number of packs per day); ②A history of drug use, alcohol abuse (average weekly consumption of ≥14 units of alcohol: 1 unit = 285 mL for beer, 25 mL for spirits, or 100 ml for wine) or drug abuse in the year prior to screening;

• Have participated in other clinical studies and used investigational drugs containing active ingredients within 30 days prior to screening, or have been within 5 half-lives of investigational drugs at the time of screening (whichever is older);

• Subjects who are pregnant (screening or baseline blood pregnancy test positive) or who plan to become pregnant while breastfeeding or during the study; ⑥Other reasons deemed unsuitable for study participation by the researcher.
• Excessive alcohol consumption and drug abuse were prohibited throughout the study period (the definition of excessive alcohol consumption is the same as exclusion criterion IV.2).

• Smoking (including e-cigarettes) was prohibited throughout the study period.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Guangdong Hengrui Pharmaceutical Co., Ltd

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

West China Hospital, Sichuan University

Chengdu, Sichuan, China

Countries

China

Central Contacts

Zi Lin

Role: CONTACT

zi.lin.zl30@hengrui.com

+0518-81220121

Other Identifiers

SHR-4597-201

Identifier Type: -

Identifier Source: org_study_id